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Abstract
Background: Ovarian carcinoma represents about 4% of all cancers diagnosed in women worldwide. Mortality rate
is high, over 50%, mainly due to late diagnosis. Currently there are no acceptable screening techniques available,
although ovarian cancer belongs to the group of malignancies for which mortality could be dramatically reduced
by early diagnosis.
In a recently published study, we clearly demonstrated that human ovarian carcinoma tissues can be characterized
by a specific odour, detectable by a trained dog. Another recent study confirmed these results using an electronic
nose.
Methods: In the present work, we examined whether the cancer-specific odour can also be found in the blood.
Two specially trained dogs were used. Both ovarian cancer tissues and blood from patients with ovarian carcinoma
were tested.
Results: The tissue tests showed sensitivity of 100% and specificity of 95%, while the blood tests showed sensitivity
of 100% and specificity of 98%.
Conclusions: The present study strongly suggests that the characteristic odour emitted by ovarian cancer samples
is also present in blood (plasma) taken from patients with the disease. This finding opens possibilities for future
screening of healthy populations for early diagnosis of ovarian carcinoma. A future challenge is to develop a
sensitive electronic nose for screening of ovarian carcinoma by testing the blood/plasma to detect the disease at a
stage early enough for treatment to be effective.
Background
Worldwide, there are more than 204,000 new cases of
ovarian cancer annually, accounting for around 4% of all
cancers diagnosed in women. Incidence rates vary con-
siderably, with the highest rates in the United States and
Northern Europe and the lowest rates in Africa and Asia.
Around 43,000 cases occur each year in Europe, and
22,000 in the USA. In Sweden, the disease represents
3.1% of all cancer cases in women, totalling about 900
cases per year. Despite this relatively low incidence rate,
it is the fifth most common cause of cancer death in
women.
Because of the high mortality rates, ovarian cancer is
one of several diseases that fulfil some of the criteria
necessary for the introduction of population screening:
it is an important health problem, and early detection is
associated with improved outcomes. Potential screening
tests for ovarian cancer have not yet been shown to
reduce mortality, although both ultrasound and tumour
markers can detect a significant proportion of ovarian
cancers preclinically. Currently, there is no accepted
screening programme for ovarian cancer [1-3].
In a recently published study, we clearly demonstrated
that human ovarian carcinoma tissues can be character-
ized by a specific odour, detectable by a trained dog.
The same study showed that a dog can be trained to
distinguish between different histopathological types and
grades of ovarian carcinomas, including borderline
tumours, as well as different healthy control samples [4].
Double-blind tests showed 100% sensitivity and 97.5%
specificity. Moreover, the odour of ovarian carcinomas
seems to differ from those of other gynaecological
malignancies, such as cervical, endometrial, and vulvar
carcinomas, suggesting that different malignancies have
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different odour characteristics. The study further
showed that early-stage and low-grade ovarian carcino-
mas emit the same specific smell as advanced tumours.
These results suggest that the specific cancer odour may
be used for screening, early diagnosis, and differential
diagnosis of different malignant diseases in the future,
when it becomes technologically possible.
Detection of other malignancies by dogs, such as mel-
anoma [5] and bladder [6], breast, and lung cancer [7],
has also been reported in peer-reviewed scientific
journals.
Besides dog studies, different technical methods such
as gas chromatography and mass spectrometry (GC/
MS), [8] gas chromatography (GC)-based arrays, [9] and
nanoparticle-polymer sensor arrays [10] have been used
to detect malignant cells in vitro.
In our last study [11], volatile signals emitted by
human seropapillary ovarian carcinoma samples and
healthy tissues such as fallopian tube, myometrium, and
postmenopausal ovarium were analyzed using an elec-
tronic nose. The electronic nose correctly classified
84.4% of cancerous tissues and 86.8% of the control
material. These results confirm the basic results from
our dog study; that is, the ovarian cancer samples emit
specific odour/volatile signals. Although the study was
small, the results offer some indication that early elec-
tronic detection of ovarian carcinoma may be possible.
One important challenge in this line of cancer
research is to find suitable target(s) for diagnostic use;
the blood offers a possible option.
The aim of this study was to test whether the specific
odour emitted by ovarian carcinomas and borderline
ovarian tumours can be detected by trained dogs in
blood from patients with these diseases.
Methods
The dogs
Two dogs were used: Hanna, a 7-year-old black
Giant Schnauzer (chip no. 967000000389928), and
Lotti, a 3-year-old black Giant Schnauzer (chip no.
098100311386). Hanna was previously trained to detect
ovarian carcinoma samples, and the test results were
published in 2008 [4]. In the present study, she was
trained over the course of 9 months to detect blood
samples from ovarian carcinoma patients, and during
this time she did not sniff carcinoma samples. Lotti,
who had not previously been trained, was trained dur-
ing the same time period to detect ovarian carcinoma
samples. Lotti had never sniffed blood samples before
the test series.
Training
The training method is described in detail elsewhere; [4]
a brief overview is given below.
Learning odour signature
Training was initially designed as a selection model,
resembling the training of sniffer dogs. In brief, the dog
was encouraged to sniff a few rags attached to pieces of
string and placed on the floor. One of them contained
an ovarian cancer sample. When the dog showed inter-
est in the target, the handler quickly snatched it away.
This was repeated several times.
Learning odour discrimination
When the dog was capable of identifying even low con-
centrations of the target vapour (finding the hidden
tumour), we began using non-target odours as controls.
Target and non-target samples were placed in glass con-
tainers, which were covered with perforated lids and
placed inside wooden boxes (25 cm × 25 cm × 25 cm).
The boxes and containers were cleaned with 95% alco-
hol after each run. We initially used only one control
specimen, and the dog was permitted to choose the
right parcel and disregard the control. Step by step, we
increased the number of control samples to five (the
combination of five controls and one target was consid-
ered a run). To minimize external influence, the exer-
cises were carried out in several training rooms in
random sequence.
Learning to distinguish extraneous odours
Although target and control samples were handled care-
fully in this phase of the training, other components
such as boxes and glass containers were contaminated
by different individuals, including the handler. However,
this contamination had no observable influence on the
dog’s target identification during this last period of
training.
Tumour and blood samples
Ovarian carcinoma samples consisting of different histo-
pathological types of various grades and stages, includ-
ing borderline tumours, were used during the training
period [4]. Tumour material was collected at primary
surgery, before chemotherapy. It was taken from the pri-
mary tumour in the pelvis (from the ovarium if possible,
at early stages) but not from the peritoneum. All
tumours were assessed by the same pathologist in accor-
dance with regional treatment guidelines for gynaecolo-
gical malignancies in western Sweden. The tumour
samples were stored in small plastic tubes, preserved
immediately at -20°C, and transported to our tumour
bank (Ethical Committee license number: S-154-02),
where they were kept at -80°C. Each tumour was divided
into 10-30 samples of about 3 mm × 3 mm × 3 mm,
and thawed at room temperature for 15-30 minutes
before being used in the training. For the test sections,
other gynaecological tumour samples, such as cervical,
vulvar, and endometrial carcinomas, were also taken
from this tumour bank and treated identically to the
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ovarian carcinomas. Sample imprints for cytological
examination were performed on all tumours and all
controls. The imprints were examined to verify the pre-
sence of malignancy (established when at least 75% of
cells were malignant). Controls were accepted only in
the complete absence of malignant cells.
Blood samples were obtained before primary surgery
from patients with ovarian carcinoma and from patients
with cervical, vulvar, and endometrial carcinomas. These
samples were taken in EDTA tubes, then centrifuged at
3000 rpm for 10 min. and plasma pots over the small
plastic tubes. The rest of the plasma samples after
undergoing CA-125 analysis, were kept at -80°C in our
tumour bank (Ethical Committee license number:
S-220-08). Blood samples with >500 IU CA-125 values
were used for training, with one drop being placed in a
small plastic dish inside each box.
Median donor age was 67 years (range: 35-79) for tis-
sue samples and 63 years (range: 45-77) for blood sam-
ples. Tissue and blood samples used during the training
period were not used in the tests.
Controls
Abdominal fat and muscle (myomas), and healthy postme-
nopausal ovarium samples were used as controls. Control
blood (plasma) samples were collected from young,
healthy female individuals. However, in some cases we
also used blood samples from male individuals, including
handlers. This had no observable influence on the dog’s
target identification. Control plasma samples were treated
identically to the targets. Median donor age was 65 years
(range: 40-81) for tissue samples and 41 years (range:
27-67) for blood samples. Tissues and blood samples used
during the training period were not used in the tests.
Test design
Tests were carried out according to the double-blind
principle; both test leader and handler were blinded to
the location of the target samples, and were present in
the test location only when the dogs were working. The
dogs were tested in four sections, two on day 1 and two
on day 2. Each section was composed of ten runs, and
each run included six boxes; five of the boxes contained
control materials and the remaining box contained the
target material. Placement of the target box was changed
by an outside assistant between each run. Section 1 (day
1): Lotti sniffed tissues; Section 2 (day 1): Hanna sniffed
blood; Section 3 (day 2): Lotti sniffed blood; Section 4
(day 2): Hanna sniffed tissues. The tests were documen-
ted on paper and DVD.
Dog’s response
A positive response was defined as indicating the target
box by scratching with foreleg(s) and lying down or
sniffing at, but not indicating the control samples.
A negative response was defined as indicating a control
box and not indicating the target.
Statistical methods
Sensitivity and specificity were calculated in the same
way as for diagnostic testing. That is, the sensitivity (or
the true positive rate) of the test was the proportion of
cancer samples that were correctly identified by the dog,
and the specificity (or the true negative rate) was the
proportion of control samples negatively indicated by
the dog.
Binomial probability distribution was used to compare
the performance of the dog with a random selection of
sample boxes. Each test consisted of ten runs, each of
which included one target sample and five controls.
Under the assumption of random positive indication by
the dog, the number of correctly identified runs was a
binomial distribution with a 1/6 probability of success
(Table 1).
Results and Discussion
Section 1: The dog correctly identified all cancer samples,
giving a sensitivity of 100%. Two controls out of 50 were
indicated, giving a specificity of 96% (Tables 2 and 3).
The probability of the dog getting at least 8 out of 10
runs completely correct entirely by chance (assuming
the two indicated controls belonged to different runs)
was 8.43*10-7.
Section 2: The dog correctly identified all plasma sam-
ples, both from cancer patients and healthy controls, giv-
ing sensitivity and specificity of 100% (Tables 4 and 5).
The probability of the dog getting all 10 runs comple-
tely correct entirely by chance was 1.65*10-8.
Section 3: The dog correctly identified all plasma sam-
ples taken from patients with ovarian carcinoma (sensi-
tivity = 100%), and also indicated two out of 50 control
samples, giving a specificity of 96% (Tables 6 and 7).
The probability of the dog getting at least 8 out of 10
runs completely correct entirely by chance (assuming
the two indicated controls belonged to different runs)
was 8.43*10-7.
Section 4: The sensitivity was again 100%, and the dog
indicated 3 out of 50 control tissues including other
gynaecological carcinomas, giving a specificity of 94%
(Tables 8 and 9).
Table 1 Calculated sensitivity and specificity
Dog indication Cancer Control Sample
positive a b a + b
Negative c d c + d
a + c b + d n
Sensitivity = a/(a + c), and specificity = d/(b + d).
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The probability of the dog getting at least 7 out of 10
runs completely correct entirely by chance (assuming
the three indicated controls belonged to different runs)
was 1.94*10-5.
When the results were pooled by sample type, the tis-
sue tests showed a sensitivity of 100% and a specificity
of 95%, and the plasma tests showed a sensitivity of
100% and a specificity of 98%.
This study is the first presentation of a specific odour
emitted by human plasma from ovarian cancer patients.
In addition, it reveals the important observation that
trained dogs can discriminate between plasma samples
from ovarian cancer patients and plasma taken from
patients with other malignancies such as endometrial,
cervical, and vulvar carcinomas.
The present study also confirms results from our pre-
vious work, in which we showed that a trained dog
could discriminate different histopathological types and
grades of ovarian carcinoma tissues, including borderline
tumours, from healthy control samples including post-
menopausal ovary. The dog could also discriminate
ovarian carcinoma tissues from all other gynaecological
malignancies. Sensitivity and specificity rates in the dou-
ble-blind test series were 100% and 97.5%, respectively
[4]. In the present study, the sensitivity and specificity
Table 2 Dog’s responses in Section 1 (Dog: Lotti;
Material: tissues)
Box 1 2 3 4 5 6
Corp58 Myoma Myoma 1786 Myoma V
Corp58 Myoma Fat Myoma 285 V
Corp58 443 Myoma Myoma Ov V
Corp58 Myoma 5377 Myoma Myoma Fat
425 Fat Corp58 Myoma Myoma V
Myoma Myoma Coll2 270 Fat Myoma
Myoma Ov Corp73 V Myoma 5005
Fat 5011 Corp58 Fat Myoma Myoma
Myoma Myoma Corp73 Fat 5039 Ov
Myoma Fat 466 V Fat Myoma
xxxx = target
Corp = endometrial carcionoma; Coll = Cervical carcinoma; V = vulvar
carcinoma; Myoma = muscle from uterine walls (healthy individuals); Fat =
abdominal, intraperitoneal fats from healthy individuals; Ov = healthy
postmenopausal ovarium samples
Dog’s responses:
Positive (bold)
Negative (monospace)
Table 3 Clinicopathological features in Section 1 (Dog:
Lotti; Material:tissues)
Tissue CA-125 U/ml Histology Grade Stage Diagnosis
1786 >200 seropapillary 2 III/C Ca. ovari
285 < 35 mucinous III Borderline
443 500 seropapillary 3 III/C Ca. ovari
5377 100 mucinous 1 I/A Ca. ovari
425 154 serous III/A Borderline
270 180 carcinosarcoma III/B Ca. ovari
5005 <35 endometroid 1 I/B Ca. ovari
5011 80 endometroid 3 II/B Ca. ovari
5039 195 carcinosarcoma II/B Ca. ovari
466 - mucinous 3 III/B Ca. ovari
V <35 squamous 2 II Ca. vulvae
Corp58 <35 endometroid 3 II/A Ca. corp. ut.
Corp73 <35 endometroid 2 I/B Ca. corp. ut.
Coll2 <35 squamous 3 III/A Ca. colli ut.
Table 4 Dog’s responses in Section 2 (Dog: Hanna;
Material: plasma)
Box 1 2 3 4 5 6
V 8783 Corp1 XX Coll XX
V X Corp1 XX Coll 3622
V XX X 1200 Corp1 XX
3712 X Corp2 V Coll XX
Coll XX Corp1 V 3607 X
Coll XX 2246 V Corp1 Corp2
3609 X Coll V Corp2 XX
XX XX Coll V Corp2 2124
X 2192 Coll XX Corp2 XX
XX Corp2 Coll V 3654 XX
xxxx= target
V = vulvar carcinoma; Coll = cervical carcinoma; Corp = endometrial
carcinoma; × = plasma obtained from healthy female individuals; XX = plasma
obtained from healthy male individuals
Responses:
Positive (bold)
Negative (monospace)
Table 5 Clinicopathological features in Section 2 (Dog:
Hanna; Material: plasma)
Plasma CA-125 Histology Grade Stage Diagnosis
8783 <35 mucinous I/A Borderline
3622 <35 endometroid 3 III/B Ca. ovari
1200 >500 seropapillary 2 III/B Ca. ovari
3712 <35 mucinous II/B Borderline
3607 <35 seropapillary 3 III/C Ca. ovari
2246 >100 seropapillary 2 III/C Ca. ovari
3609 <35 adenocarcinoma 2 I/B Ca. ovari
2124 >500 seropapillary 3 III/C Ca. ovari
2192 >500 seropapillary 2 III/A Ca. ovari
3654 <35 adenocarcinom 3 IV Ca. ovari
Vulva <35 squamous 2 II Ca. vulvae
Corp 1 <35 endometroid 3 I/C Ca. corp. ut.
Corp 2 <35 endometroid 3 I/C Ca. corp. ut.
Coll <35 adenocarcinoma 2 II/A Ca. colli ut.
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for the two tissue tests (Sections 1 and 4) were 100%
95%, respectively.
The present study strongly suggests that the charac-
teristic odour emitted by ovarian cancer samples is also
present in blood (plasma) taken from patients with the
disease. This observation suggests that the specific can-
cer odour in the blood/plasma may be used for screen-
ing, diagnosis, and differential diagnosis of different
malignant diseases. The past decade has seen an increas-
ing amount of research into different technical methods
of identifying the characteristic volatile organic com-
pound (VOC) signals emitted by malignancies. Methods
such as gas chromatography and mass spectrometry, [8]
gas chromatography-based arrays, [9] and nanoparticle-
polymer sensor arrays [10]-"chemical noses” and electro-
nic noses-have been used to detect malignant cells in
vitro, and diagnostic methods for lung cancer using
exhaled breath have also been investigated [12].
Our recently completed study presents the first evidence
that an electronic nose can provide an easy technique to
distinguish the VOC signals emitted by human ovarian
carcinomas and healthy human fallopian tube, myome-
trium, and postmenopausal ovary, respectively [11]. The
electronic nose showed a sensitivity of 84.4% and a
Table 6 Dog’s responses in Section 3 (Dog: Lotti;
Material: plasma)
Box 1 2 3 4 5 6
V X Corp1 X Coll 2124
X XX 3646 X Corp1 Coll
7673 XX V X Coll Corp1
Coll X V XX 2192 Corp1
Coll 6647 X XX X Corp1
Coll Corp2 V X XX 3631
X Corp2 V 2139 X X
3657 Corp1 X Coll XX XX
XX X Corp1 Coll 2144 X
XX Corp2 3635 Coll V X
xxxx = target
V = vulvar carvinoma; Coll = cervical carcinoma; Corp = endometrial
carcinoma; × = plasma
obtained from healthy female individuals; XX = plasma, obtained from healthy
male individuals
Responses:
Positive (bold)
Negative (monospace)
Table 7 Clinicopathological features in Section 3 (Dog:
Lotti; Material: plasma)
Plasma CA-125 Histology Grade Stage
2124 >500 seropapillary 3 III/C
3646 <35 endometroid 2 III/B
7673 <35 mucinous – I/C
2192 >500 seropapillary 2 III/A
6647 <35 mucinous - I/B
3631 <35 seropapillary 2 III/B
2139 >200 carcinosarcom - III/A
3657 <35 seropapillary 1 III/C
2144 >500 adenocarcinoma 3 II/A
3635 <35 seropapillary 3 III/B
Vulva <35 squamous 2 II
Corp 1 <35 endometroid 3 I/C
Corp 2 <35 endometroid 3 I/C
Coll <35 adenocarcinoma 2 II/A
Table 8 Dog’s responses in Section 4 (Dog: Hanna;
Material: tissues)
Box 1 2 3 4 5 6
Fat 258 Myoma V Corp V
Corp58 Myoma Fat Myoma Corp 1786
5005 Fat Myoma Myoma Ov V
Corp58 Myoma Fat 5039 Myoma Fat
V Fat Fat Fat Corp 147
Fat V 425 V Fat Fat
Myoma 5011 Fat Fat Corp73 Fat
V Corp58 Corp58 Fat 270 Myoma
5377 Myoma Corp73 Fat V Ov
Myoma Fat Fat 443 Fat Myoma
xxxx = target
Corp = endometrial carcinoma; Coll = Cervical carcinoma; V = Vulvar
carcinoma; Myoma = muscle from uterine walls (healthy individuals); Fat =
abdominal, intraperitoneal fats from healthy individuals; Ov = healthy
postmenopausal ovarium samples
Dog’s responses:
Positive (bold)
Negative (monospace)
Table 9 Clinicopathological features in Section 4 (Dog:
Hanna; Material: tissues)
Tissue CA-125 U/ml Histology Grade Stage Diagnosis
1786 >200 seropapillary 2 III/C Ca. ovari
285 <35 mucinous III Borderline
443 500 seropapillary 3 III/C Ca. ovari
5377 100 mucinous 1 I/A Ca. ovari
425 154 serous III/A Borderline
270 180 carcinosarcoma III/B Ca. ovari
5005 <35 endometroid 1 I/B Ca. ovari
5011 80 endometroid 3 II/B Ca. ovari
5039 195 carcinosarcoma II/B Ca. ovari
147 - mucinous 3 II/B Ca. ovari
V <35 squamous 2 II Ca. vulvae
Corp58 <35 endometroid 3 II/A Ca. corp. ut.
Corp73 <35 endometroid 2 I/B Ca. corp. ut.
Coll2 <35 squamous 3 III/A Ca. colli ut.
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specificity of 86.8% in the total material. However, in that
study we did not test our electronic nose on blood/plasma
samples or on malignancies other than ovarian carcinoma.
It is not easy to make comparisons between the pre-
sent study and other dog studies. Two of the available
dog studies used training methods that differed from
those in the present study, as well as different target
materials [6,7]. A third study was, like ours, based on
tissue material, but included only a very limited number
of tissues [5].
Our observations from dog studies show that trained
dogs can detect even as small a quantity as 20 ovarian
carcinoma cells on the abdominal fat (data not shown).
Thus, the cancer-specific odour/VOC components are
emitted even in early phases of tumour development.
We believe that a significant challenge for future experi-
ments is to construct more sensitive electronic noses,
not only for early detection but also for differential diag-
nosis between malignancies. If the electronic nose is to
be used for screening of ovarian carcinoma by testing
the blood/plasma, it must be able to detect the disease
in the early stages, when treatment is effective.
It is difficult to compare the sensitivity of a dog’s nose
to that of the electronic nose. Dogs detect only odour
molecules, whereas electronic noses may also detect sev-
eral odourless compounds (e.g. CH4). The two systems
may thus detect different levels of sensitivity. Our
experience suggests that trained dogs could be used
under controlled circumstances in experiments as com-
plementary “instruments” to further explore this very
interesting new property of malignancies. Similar sug-
gestions were published by Gordon et al. [13].
Conclusion
The present study strongly suggests that the characteris-
tic odour emitted by ovarian cancer samples is also pre-
sent in blood (plasma) taken from patients with the
disease.
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